China Medical System Gains NMPA Nod to Begin Trials of INHBE-Targeting Obesity Drug

SGX Filings

Mar 04

China Medical System Holdings Limited announced that on Mar, 4 2026 China’s National Medical Products Administration approved the company’s application to start clinical trials of CMS-D008, a self-developed INHBE-targeting small nucleic acid (siRNA) injection for overweight and obese individuals.

CMS-D008 is designed for subcutaneous administration and works by reducing hepatic expression of the inhibin subunit beta E gene (INHBE), thereby lowering Activin E protein levels to inhibit Activin E-ALK7 signaling and decrease fat accumulation. Preclinical studies showed the candidate produced sustained INHBE suppression, enhanced weight loss through fat-mass reduction while preserving lean mass, and exhibited a favorable safety profile.

The company said CMS-D008 may complement its GLP-1R/GCGR dual agonist CMS-D005, which is in clinical development for weight loss and liver fat reduction. The two investigational drugs could potentially offer combined, long-term benefits in obesity and metabolic disease management.

China Medical System is preparing to launch the approved clinical trials and aims to accelerate development and commercialization using its existing cardiovascular and metabolic-disease network. The company advised shareholders and investors to exercise caution when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1150008716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150008716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150008716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150008716","market":"sg","top_or_hot":-1,"title":"China Medical System Gains NMPA Nod to Begin Trials of INHBE-Targeting Obesity Drug","media":"SGX Filings","content":"<p>China Medical System Holdings Limited announced that on Mar, 4 2026 China’s National Medical Products Administration approved the company’s application to start clinical trials of CMS-D008, a self-developed INHBE-targeting small nucleic acid (siRNA) injection for overweight and obese individuals.</p>\n<p>CMS-D008 is designed for subcutaneous administration and works by reducing hepatic expression of the inhibin subunit beta E gene (INHBE), thereby lowering Activin E protein levels to inhibit Activin E-ALK7 signaling and decrease fat accumulation. Preclinical studies showed the candidate produced sustained INHBE suppression, enhanced weight loss through fat-mass reduction while preserving lean mass, and exhibited a favorable safety profile.</p>\n<p>The company said CMS-D008 may complement its GLP-1R/GCGR dual agonist CMS-D005, which is in clinical development for weight loss and liver fat reduction. The two investigational drugs could potentially offer combined, long-term benefits in obesity and metabolic disease management.</p>\n<p>China Medical System is preparing to launch the approved clinical trials and aims to accelerate development and commercialization using its existing cardiovascular and metabolic-disease network. The company advised shareholders and investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System Gains NMPA Nod to Begin Trials of INHBE-Targeting Obesity Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System Gains NMPA Nod to Begin Trials of INHBE-Targeting Obesity Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-03-04 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited announced that on Mar, 4 2026 China’s National Medical Products Administration approved the company’s application to start clinical trials of CMS-D008, a self-developed INHBE-targeting small nucleic acid (siRNA) injection for overweight and obese individuals.</p>\n<p>CMS-D008 is designed for subcutaneous administration and works by reducing hepatic expression of the inhibin subunit beta E gene (INHBE), thereby lowering Activin E protein levels to inhibit Activin E-ALK7 signaling and decrease fat accumulation. Preclinical studies showed the candidate produced sustained INHBE suppression, enhanced weight loss through fat-mass reduction while preserving lean mass, and exhibited a favorable safety profile.</p>\n<p>The company said CMS-D008 may complement its GLP-1R/GCGR dual agonist CMS-D005, which is in clinical development for weight loss and liver fat reduction. The two investigational drugs could potentially offer combined, long-term benefits in obesity and metabolic disease management.</p>\n<p>China Medical System is preparing to launch the approved clinical trials and aims to accelerate development and commercialization using its existing cardiovascular and metabolic-disease network. The company advised shareholders and investors to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1150008716","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150008716","pubTimestamp":1772626665,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited announced that on Mar, 4 2026 China’s National Medical Products Administration approved the company’s application to start clinical trials of CMS-D008, a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"康哲药业获得NMPA批准开始INHBE靶向肥胖药物试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited announced that on Mar, 4 2026 China’s National Medical Products Administration approved the company’s application to start clinical trials of CMS-D008, a self-developed INHBE-targeting small nucleic acid (siRNA) injection for overweight and obese individuals.\nCMS-D008 is designed for subcutaneous administration and works by reducing hepatic expression of the inhibin subunit beta E gene (INHBE), thereby lowering Activin E protein levels to inhibit Activin E-ALK7 signaling and decrease fat accumulation. Preclinical studies showed the candidate produced sustained INHBE suppression, enhanced weight loss through fat-mass reduction while preserving lean mass, and exhibited a favorable safety profile.\nThe company said CMS-D008 may complement its GLP-1R/GCGR dual agonist CMS-D005, which is in clinical development for weight loss and liver fat reduction. The two investigational drugs could potentially offer combined, long-term benefits in obesity and metabolic disease management.\nChina Medical System is preparing to launch the approved clinical trials and aims to accelerate development and commercialization using its existing cardiovascular and metabolic-disease network. The company advised shareholders and investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}